Fort Worth-based Galderma Laboratories LP has gained full rights to distribute five aesthetic dermatology products from Valeant Pharmaceuticals International Inc. in the United States and Canada. The agreement allows Galderma to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in skin care and treatment. “The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics markets,” said Stuart Raetzman, vice president of Galderma for North America. “Demographics, social and cultural drivers, as well as an improving economy, make this an ideal time for Galderma to expand its geographic footprint in aesthetic and corrective medicine to the United States and Canada.” Galderma will pursue to distribute the acquired products through the existing distribution partner.
Betty Dillard email@example.com